Abstract
PIK3CA pathogenic variants are responsible for a group of overgrowth syndromes, collectively known as PIK3CA-Related Overgrowth Spectrum (PROS). These gain-of-function variants arise postzygotically, and, according to time of onset, kind of embryonal tissue affected and regional body extension, give rise to heterogeneous phenotypes. PROS rarity and heterogeneity hamper the correct estimation of its epidemiology. Our work represents the first attempt to define the prevalence of PROS according to the established diagnostic criteria and molecular analysis and based on solid demographic data. We assessed the prevalence in Piedmont Region (Italy), including in the study all participants diagnosed with PROS born there from 1998 to 2021. The search identified 37 cases of PROS born across the 25-year period, providing a prevalence of 1:22,313 live births. Molecular analysis was positive in 81.0% of participants. Taking into account the cases with a detected variant in PIK3CA (n = 30), prevalence of molecularly positive PROS was 1:27,519.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
Depersonalized data that support the findings of this study are available within the paper and/or are available on request from the corresponding author AM.
References
Keppler-Noreuil KM, Rios JJ, Parker VER, Semple RK, Lindhurst MJ, Sapp JC, et al. PIK3CA-related overgrowth spectrum (PROS): Diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am J Med Genet Part A. 2015;167:287–95. https://doi.org/10.1002/ajmg.a.36836.
Lindhurst MJ, Parker VER, Payne F, Sapp JC, Rudge S, Harris J, et al. “Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nat Genet. 2012;44:928–33. https://doi.org/10.1038/ng.2332.
Harnarayan P, Harnanan D. The Klippel-Trénaunay Syndrome in 2022: Unravelling Its Genetic and Molecular Profile and Its Link to the Limb Overgrowth Syndromes. Vasc Health Risk Manag. 2022;18:201–9. https://doi.org/10.2147/VHRM.S358849.
Rios JJ, Paria N, Burns DK, Israel BA, Cornelia R, Wise CA, et al. Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. Hum Mol Genet. 2013;22:444–51. https://doi.org/10.1093/hmg/dds440.
Goss JA, Konczyk DJ, Smits P, Sudduth CL, Bischoff J, Liang MG, et al. Diffuse capillary malformation with overgrowth contains somatic PIK3CA variants. Clin Genet. 2020;97:736–40. https://doi.org/10.1111/cge.13702.
Sarma K, Nayak MK, Mishra B, Gaikwad SB. Megalencephaly-Capillary Malformation-Polymicrogyria Syndrome (MCAP): A Rare Dynamic Genetic Disorder. Cureus. 2022;14:e25123. https://doi.org/10.7759/cureus.25123.
Carli D, Kalantari S, Manicone R, Coppo P, Francia di Celle P, La Selva R, et al. Kaposiform hemangioendothelioma further broadens the phenotype of PIK3CA-related overgrowth spectrum. Clin Genet. 2021;100:624–7. https://doi.org/10.1111/cge.14047.
Weng J, Yang Y, Song D, Huo R, Li H, Chen Y, et al. Somatic MAP3K3 mutation defines a subclass of cerebral cavernous malformation. Am J Hum Genet. 2021;108:942–50. https://doi.org/10.1016/j.ajhg.2021.04.005.
Mussa A, Leoni C, Iacoviello M, Carli D, Ranieri C, Pantaleo A et al. Genotypes and phenotypes heterogeneity in PIK3CA-related overgrowth spectrum and overlapping conditions: 150 novel patients and systematic review of 1007 patients with PIK3CA pathogenetic variants.” J Med Genet. 1–11:2022, https://doi.org/10.1136/jmedgenet-2021-108093.
Madsen RR, Vanhaesebroeck B, Semple RK. Cancer-Associated PIK3CA Mutations in Overgrowth Disorders. Trends Mol Med. 2018;24:856–70. https://doi.org/10.1016/j.molmed.2018.08.003.
Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, Parker VER, Blumhorst C, Darling T, et al. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. Am J Med Genet Part A. 2014;164:1713–33. https://doi.org/10.1002/ajmg.a.36552.
Chang F, Liu L, Fang E, Zhang G, Chen T, Cao K, et al. Molecular Diagnosis of Mosaic Overgrowth Syndromes Using a Custom-Designed Next-Generation Sequencing Panel. J Mol Diagn. 2017;19:613–24. https://doi.org/10.1016/j.jmoldx.2017.04.006.
Mirzaa G, Timms AE, Conti V, Boyle EA, Girisha KM, Martin B et al. PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution. JCI Insight. 2016. https://doi.org/10.1172/jci.insight.87623.
Kuentz P, St-Onge J, Duffourd Y, Courcet JB, Carmignac V, Jouan T, et al. Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing. Genet Med J Am Coll Med Genet. 2017;19:989–97. https://doi.org/10.1038/gim.2016.220.
Carli D, Ferrero GB, Fusillo A, Coppo P, La Selva R, Zinali F, et al. A new case of Smith-Kingsmore syndrome with somatic MTOR pathogenic variant expands the phenotypic spectrum to lateralized overgrowth. Clin Genet. 2021;99:719–23. https://doi.org/10.1111/cge.13931.
Chang CA, Perrier R, Kurek KC, Estrada-Veras J, Lehman A, Yip S, et al. Novel findings and expansion of phenotype in a mosaic RASopathy caused by somatic KRAS variants. Am J Med Genet A. 2021;185:2829–45. https://doi.org/10.1002/ajmg.a.62356.
Mussa A, Carli D, Cardaropoli S, Ferrero GB, Resta N. Lateralized overgrowth with vascular malformation caused by a somatic PTPN11 pathogenic variant: Another piece added to the puzzle of mosaic RASopathies. Genes Chromosom Cancer. 2022;61:689–95. https://doi.org/10.1002/gcc.23086.
Siegel DH, Cottrell CE, Streicher JL, Schilter KF, Basel DG, Baselga E, et al. Analyzing the Genetic Spectrum of Vascular Anomalies with Overgrowth via Cancer Genomics. J Investig Dermatol. 2018;138:957–67. https://doi.org/10.1016/j.jid.2017.10.033.
Mussa A, Carli D, Cardaropoli S, Ferrero GB, Resta N. Lateralized and Segmental Overgrowth in Children. Cancers (Basel). 2021;13. https://doi.org/10.3390/cancers13246166.
Data on file. Novartis Pharmaceuticals Corp; 2020. https://www.prosspectrum.com/about-pros/pros-overview/. (accessed Dec. 02, 2022).
Acknowledgements
We are grateful to the patients and their families who made this research possible by consenting to the use of data collected as part of their care. We thank the Italian Association of individuals with PROS (Associazione Italiana Macrodattilia e PROS—APS) who contributed to this study.
Funding
No specific grant for this research was received from any funding agency in the public, commercial or not-for-profit sectors.
Author information
Authors and Affiliations
Contributions
Conceptualization: AM, GR. Formal analysis and methodology: AM, GR. Investigation: AM, GR, SC, DC, ML, AG, PC, RLS, MP, RB, AT, CR. Resources: AM, SC, DC, ML, AG, PC, RLS, MP, RB, AT, CR, NR. Supervision: NR. Writing-original draft: AM, GR. Writing-review and editing: AM. All other authors approved this paper.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval
Given the retrospective nature of the study, approval by Ethic Committee was not required. Informed consent to genetic analysis on peripheral blood, tissue biopsy, or other samples was obtained by parents of participants and archived by authors according to the local ethic committee’s policy. Individual data included in this paper have been de-identified and presented in aggregate. The study was conducted in accordance with the ethical principles enshrined in the Helsinki Declaration.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Reynolds, G., Cardaropoli, S., Carli, D. et al. Epidemiology of the disorders of the Pik3ca-related overgrowth spectrum (Pros). Eur J Hum Genet 31, 1333–1336 (2023). https://doi.org/10.1038/s41431-023-01414-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41431-023-01414-9
This article is cited by
-
Deep phenotyping and population-level data can help resolve genomic variants
European Journal of Human Genetics (2023)